Ping Yin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ping Yin has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Bin Liu
Anti-Cancer Research Center, Medical College, Xiamen University, Xiamen, China
1 shared publication - Donghai Yang
Anti-Cancer Research Center, Medical College, Xiamen University, Xiamen, China
1 shared publication - Feng Yan
Department of Gastrointestinal Surgery, Zhongshan Hospital Xiamen University, School of Medicine, Xiamen University
1 shared publication - Guohong Zhuang
Anti-Cancer Research Center, Medical College, Xiamen University, Xiamen, China
1 shared publication - Qiang Wen
Anti-Cancer Research Center, Medical College, Xiamen University, Xiamen, China
1 shared publication - Sibo Yuan
Zhongshan Hospital, Xiamen University, Xiamen, China
1 shared publication
Latest Publications
- Open Access
- 6 June 2012
- Published by Springer Nature in BMC Immunology
- Vol. 13 (1) , 28
Significance of decoy receptor 3 (Dcr3) and external-signal regulated kinase 1/2 (Erk1/2) in gastric cancer
Background: Decoy receptor 3 (DcR3), a member of the tumor necrosis factor receptor (TNFR) superfamily, is associated with anti-tumor immunity suppression. It is highly expressed in many tumors, and its expression can be regulated by the MAPK/MEK/ERK signaling pathway. The MAPK/MEK/ERK pathway has been reported to be a regulator in tumor occurrence, development and clonal expansion. External-signal regulated kinase (ERK) is a vital member of this pathway. Results: The expression of DcR3 and ERK1/2 in tumor tissues of gastric cancer patients was significantly higher than the non-cancerous group (P < 0.05). There was no statistical difference among tumor tissues from patients with different ages or gender, and even of different differentiation (P > 0.05). However, in patients with stage I gastric cancer, the DcR3 and ERK1/2 levels were significantly lower than patients with more advanced stages. Conclusions: DcR3 and ERK1/2 play a vital role in the development of gastric cancer, and they may be new markers for indicating the efficiency of gastric cancer treatment in the future.
- 6 June 2012
- Published by Springer Nature in BMC Immunology
- Vol. 13 (1) , 28
Open AccessSignificance of decoy receptor 3 (Dcr3) and external-signal regulated kinase 1/2 (Erk1/2) in gastric cancer
Background: Decoy receptor 3 (DcR3), a member of the tumor necrosis factor receptor (TNFR) superfamily, is associated with anti-tumor immunity suppression. It is highly expressed in many tumors, and its expression can be regulated by the MAPK/MEK/ERK signaling pathway. The MAPK/MEK/ERK pathway has been reported to be a regulator in tumor occurrence, development and clonal expansion. External-signal regulated kinase (ERK) is a vital member of this pathway. Results: The expression of DcR3 and ERK1/2 in tumor tissues of gastric cancer patients was significantly higher than the non-cancerous group (P < 0.05). There was no statistical difference among tumor tissues from patients with different ages or gender, and even of different differentiation (P > 0.05). However, in patients with stage I gastric cancer, the DcR3 and ERK1/2 levels were significantly lower than patients with more advanced stages. Conclusions: DcR3 and ERK1/2 play a vital role in the development of gastric cancer, and they may be new markers for indicating the efficiency of gastric cancer treatment in the future.